Johnson & Johnson: A Deep Dive Through Buffett's Lens

Johnson & Johnson is the kind of diversified, durable franchise Buffett has long respected — a portfolio of moats rather than a single bet, with a balance sheet strong enough to be boring. It rarely excites; that is often the point.

The Moat: A Portfolio of Moats

J&J spans pharmaceuticals, medical devices, and consumer health. Each segment carries its own economic moat — patent-protected drugs, regulatory and switching barriers in devices, and brand trust in consumer staples. Diversification means a patent cliff in one product is absorbed by the rest, a structural resilience few single-product pharma names enjoy.

Balance Sheet: The Ultimate Margin of Safety

Buffett prizes a fortress balance sheet as a margin of safety, and J&J has one — it is a Dividend King that has raised its payout for six decades. That financial strength removes distress risk and funds steady capital allocation through cycles. The business generates dependable owner earnings that compound for patient holders.

Valuation: Quality at a Calm Price

Because J&J grows slowly, the market rarely bids it to euphoria. For a value investor that calmness is the opportunity: a wide-moat, diversifying business with a thin chance of permanent loss. Use the live Score, Moat, and DCF cards to see whether today's price offers a margin of safety on a franchise built to outlive any single product cycle.